Tirzepatide vs Semaglutide: The Definitive Clinical Comparison

Tirzepatide and semaglutide are the two most-prescribed GLP-1 medications in the United States. They share the same drug class (incretin-based therapies), the same route of administration (weekly subcutaneous injection), and a substantially overlapping side-effect profile. They differ in mechanism, weight-loss magnitude, cardiovascular outcomes evidence, dose ceiling, and cost.

This article compares the two at the molecule level, independent of brand. Both molecules are sold under multiple brand names: tirzepatide as Mounjaro (diabetes) and Zepbound (weight loss and obstructive sleep apnea); semaglutide as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral, diabetes). Compounded versions of both molecules are available through licensed 503A pharmacies under physician oversight, including through Harbor.

The framework below is the same one Harbor’s clinical team uses when matching a new member to either compounded semaglutide ($99/mo) or compounded tirzepatide ($149/mo). For brand-specific comparisons, see Harbor’s companion pieces on tirzepatide vs Ozempic, tirzepatide vs Wegovy, tirzepatide vs Mounjaro, and tirzepatide vs Zepbound.

Semaglutide is a GLP-1 receptor agonist. It is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone your gut releases after a meal. The drug binds the GLP-1 receptor in three places: the gut, the brain, and the pancreas. The effects are slower gastric emptying, reduced appetite signaling, and stabilized blood glucose between meals.

Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone that works in concert with GLP-1. Activating both receptors at once amplifies the appetite-suppression effect, the gastric-emptying effect, and the insulin-sensitization effect. The dual mechanism is sometimes referred to as a “twincretin” approach.

The structural difference is the reason behind the larger average weight loss in clinical trials. Both drugs target the same biological pathway, but tirzepatide pulls on two levers where semaglutide pulls on one.

What this means for the patient experience

In practice, patients on tirzepatide often describe a stronger reduction in “food noise” (intrusive thoughts about eating between meals) compared with semaglutide at comparable timepoints. Both medications produce satiety, but the magnitude tends to be larger on tirzepatide. The trade-off is that tirzepatide’s mechanism also produces a slightly different side-effect timing profile, particularly around dose escalation.

The two registration trials (STEP-1 for semaglutide, SURMOUNT-1 for tirzepatide) and the head-to-head SURMOUNT-5 are the cleanest data points.

STEP-1: semaglutide 2.4 mg

The STEP-1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with overweight or obesity (without diabetes) and randomized them to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean body weight reduction was 14.9% on semaglutide compared with 2.4% on placebo. Eighty-six percent reached at least 5% weight loss and approximately 50% reached at least 15%. The full paper is available at nejm.org/doi/full/10.1056/NEJMoa2032183.

SURMOUNT-1: tirzepatide 15 mg

The SURMOUNT-1 trial, published in NEJM in 2022, enrolled 2,539 adults with overweight or obesity and randomized them to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean body weight reductions were 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo. Approximately 57% of participants on the highest dose lost 20% or more. Read at nejm.org/doi/full/10.1056/NEJMoa2206038.

SURMOUNT-5: the head-to-head

SURMOUNT-5 is the first direct head-to-head trial of tirzepatide 15 mg and semaglutide 2.4 mg. The trial enrolled 751 adults with obesity (without diabetes) and reported that tirzepatide produced approximately 47% greater relative weight loss than semaglutide at 72 weeks. The trial was conducted by Eli Lilly and reported in 2024.

Scroll the table sideways to see both columns →

Both medications share a gastrointestinal-dominant side-effect profile because the mechanism that slows gastric emptying is also the one that causes nausea. The differences come down to magnitude and titration.

Registration trial rates

• Nausea - 43.9% on semaglutide 2.4 mg vs 33.3% on tirzepatide 15 mg.
• Diarrhea - 30.0% on semaglutide vs 22.0% on tirzepatide.
• Vomiting - 24.1% on semaglutide vs 19.0% on tirzepatide.
• Constipation - 24.2% on semaglutide vs 17.0% on tirzepatide.

The lower side-effect rates on tirzepatide are likely a function of its longer titration schedule (six dose steps over 20 weeks vs five steps over 16 weeks for semaglutide). Slower titration gives the body more time to adapt to each dose level. Most gastrointestinal side effects resolve within the first 4 to 8 weeks of treatment on either medication.

Serious adverse events

Both medications carry a boxed warning for the risk of thyroid C-cell tumors observed in rodent studies. Risk in humans has not been established. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis and gallbladder disease are uncommon but documented. For symptom-by-symptom management, see Harbor’s guides on tirzepatide side effects and managing nausea on GLP-1s.

The single area where semaglutide leads tirzepatide today is the depth of cardiovascular outcomes evidence. The SELECT trial, published in NEJM in 2023, randomized 17,604 adults with established cardiovascular disease and overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo over a median of 39.8 months. Semaglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20%. Read at nejm.org/doi/full/10.1056/NEJMoa2307563.

The SELECT result extended Wegovy’s FDA indication in 2024 to include cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. It is also the basis for Medicare Part D coverage of Wegovy for that population.

Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) is ongoing with full results expected through 2027. Until that data is available, semaglutide is the GLP-1 with the strongest published cardiovascular evidence base. For patients with established cardiovascular disease, this is a meaningful clinical consideration.

The cost landscape has three layers: brand-name list prices, real out-of-pocket after insurance or savings programs, and compounded options.

Brand-name list prices

• Wegovy (semaglutide) - approximately $1,349 per month for the single-use pen.
• Ozempic (semaglutide) - approximately $968 per month for the diabetes-labeled brand.
• Zepbound (tirzepatide) - approximately $1,059 per month for autoinjector pens, with self-pay vials at approximately $499 per month for the 2.5 mg and 5 mg starting doses.
• Mounjaro (tirzepatide) - approximately $1,069 per month for the diabetes-labeled brand.

Compounded options

Harbor offers compounded semaglutide at $99 per month and compounded tirzepatide at $149 per month, both with a 12-month results guarantee, 24/7 clinician access through the patient portal, and on-time refill protection. Compounded preparations are dispensed by US-certified 503A pharmacies under physician oversight on a per-patient prescription basis. They are not FDA-approved drug products. For the regulatory framework, see Harbor’s piece on 503A and 503B compounding.

Switching between semaglutide and tirzepatide is one of the most common transitions Harbor’s clinical team manages. The standard protocol is straightforward.

Semaglutide to tirzepatide

1. Take the last semaglutide dose.
2. Wait one week.
3. Start tirzepatide at the 2.5 mg starting dose, regardless of prior semaglutide dose.
4. Titrate every four weeks: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.

Tirzepatide to semaglutide

1. Take the last tirzepatide dose.
2. Wait one week.
3. Start semaglutide at the 0.25 mg starting dose.
4. Titrate every four weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg.

Weight loss typically pauses or slows for one to two weeks during the switch and reaccelerates once the new medication reaches a therapeutic dose. Most patients find side effects equal to or milder than their original starting experience because the body has already adapted to incretin activity.

Both medications are reasonable first-line treatments for most adults with obesity. The decision factors:

Tirzepatide is usually the right call when

• You have a weight-loss target of 20% or more of starting body weight.
• Your starting BMI is 35 or higher (class II obesity).
• You have insulin resistance, prediabetes, or co-existing type 2 diabetes.
• You have obstructive sleep apnea associated with obesity (Zepbound is FDA-approved for this indication).
• You have tried semaglutide before and plateaued before reaching your goal.

Semaglutide is usually the right call when

• You have established cardiovascular disease and obesity. The SELECT trial supports semaglutide specifically for this population.
• Your weight-loss target is in the 10 to 15% range.
• You want the longest post-market safety record (semaglutide has been on the US market since 2017; tirzepatide since 2022).
• You have a history of significant GI sensitivity on prior GLP-1 attempts. Semaglutide’s lower top dose can be easier for some patients to tolerate.
• You are highly cost-sensitive and Harbor’s $99/month compounded semaglutide is the right entry point.

About 60% of new Harbor members start on compounded semaglutide and 40% start on compounded tirzepatide. The match is based on starting BMI, weight-loss goal, cardiovascular history, prior GLP-1 experience, side-effect tolerance, and cost preference. The decision is made between member and clinician at the eligibility-quiz stage and re-visited as the program progresses.

About one in five members who start on semaglutide eventually switches to tirzepatide because of plateau or insufficient efficacy. The switch is managed through the patient portal without a price increase, and the 12-month results guarantee carries forward. Both programs include 24/7 clinician access, dietitian support in the maintenance phase, on-time refill protection, and the 12-month guarantee. For the underlying biology, see Harbor’s science of GLP-1 overview. For program comparison, see how Harbor compares to other GLP-1 programs.